Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Praxis Precision Medicines, Inc.    PRAX

PRAXIS PRECISION MEDICINES, INC.

(PRAX)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
34.57(c) 34.25(c) 35.35(c) 37.16(c) 40.86(c) Last
204 099 120 386 138 313 183 047 67 704 Volume
+1.62% -0.93% +3.21% +5.12% +9.96% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -53,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -19,3x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -86,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -19,9x
Yield 2021 -
Capitalization 1 563 M 1 563 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 51
Free-Float 98,7%
More Financials
Company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive... 
More about the company
All news about PRAXIS PRECISION MEDICINES, INC.
11/23PRAXIS PRECISION MEDICINES : Management's Discussion and Analysis of Financial C..
AQ
11/20PRAXIS PRECISION MEDICINES : to Participate in Upcoming Investor Conferences
AQ
11/20Praxis Precision Medicines to Participate in Upcoming Investor Conferences
GL
11/17PRAXIS PRECISION MEDICINES, INC. : Other Events, Financial Statements and Exhibi..
AQ
11/17PRAXIS PRECISION MEDICINES : Provides Update On PRAX-114 IND Submission For The ..
AQ
11/17Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The..
GL
11/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
11/10PRAXIS PRECISION MEDICINES, INC. : Regulation FD Disclosure, Other Events, Finan..
AQ
11/09PRAXIS PRECISION MEDICINES : Provides Regulatory Update On PRAX-114 Program
AQ
11/09Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
GL
10/20PRAXIS PRECISION MEDICINES, INC. : Amendments to Articles of Inc. or Bylaws; Cha..
AQ
10/20PRAS PREC : Praxis Precision Medicines Announces Closing of Initial Public Offer..
AQ
10/20Praxis Precision Medicines Announces Closing of Initial Public Offering and E..
GL
10/15Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offeri..
GL
More news
News in other languages on PRAXIS PRECISION MEDICINES, INC.

- No features available -

More news
Chart PRAXIS PRECISION MEDICINES, INC.
Duration : Period :
Praxis Precision Medicines, Inc. Technical Analysis Chart | PRAX | US74006W1080 | MarketScreener
Technical analysis trends PRAXIS PRECISION MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 53,33 $
Last Close Price 40,86 $
Spread / Highest target 59,1%
Spread / Average Target 30,5%
Spread / Lowest Target -2,10%
EPS Revisions
Managers
NameTitle
Marcio Souza President, Chief Executive Officer & Director
Dean Jonathan Mitchell Chairman
Stuart Chaffee Chief Financial Officer
Bernard Ravina Chief Medical Officer
Steven Petrou Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
PRAXIS PRECISION MEDICINES, INC.0.00%1 563
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427